Loading...
•
Jun 30
Exact Sciences Q2 2025 Earnings Report
Exact Sciences reported record revenue and improved adjusted EBITDA in Q2 2025, leading to raised full-year guidance.
Key Takeaways
Exact Sciences delivered a strong second quarter in 2025, achieving record total revenue of $811 million, a 16% increase year-over-year. The company also significantly improved its adjusted EBITDA to $138 million, up 26%, and narrowed its net loss to $1 million. This performance was driven by robust growth in both Screening and Precision Oncology segments, and the successful launch of Cologuard Plus.
Record total second quarter revenue of $811 million, marking a 16% increase from the prior year.
Adjusted EBITDA reached $138 million, a 26% increase, with adjusted EBITDA margin improving to 17%.
Net loss significantly improved to $1 million, or $0.01 per share, compared to a $15.8 million loss in Q2 2024.
Full-year 2025 revenue and adjusted EBITDA guidance midpoints were raised by $55 million and $25 million, respectively.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
Exact Sciences has raised its full-year 2025 revenue and adjusted EBITDA guidance, reflecting strong performance and confidence in future growth.
Positive Outlook
- Total revenue guidance midpoint raised by $55 million to $3.15 billion.
- Screening revenue guidance midpoint raised by $47.5 million to $2.455 billion.
- Precision Oncology revenue guidance midpoint raised by $7.5 million to $695 million.
- Adjusted EBITDA guidance midpoint raised by $25 million to $465 million.
- Anticipated 14% year-over-year growth rate for total revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income